Cidara Therapeutics Inc (NASDAQ: CDTX) stock suffered a major decline of -13.3% on 1/24/25. The shares closed at $18.91. However, below average trading volume at 70% of normal accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -7.4% during the last week.
Current PriceTarget Research Rating
Cidara Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.